News Channels

20 Jan 2021 Doptelet® (avatrombopag) approved in the EU for treatment of ITP
20 Jan 2021 Enhertu approved in the EU for the treatment of HER2-positive metastatic breast cancer
19 Jan 2021 Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
19 Jan 2021 Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
19 Jan 2021 Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
18 Jan 2021 Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy
18 Jan 2021 Ixaka (formerly Rexgenero) launches as an integrated cell and gene therapy company
18 Jan 2021 Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
18 Jan 2021 Positive Phase 1 results in high-dose setanaxib trial
18 Jan 2021 GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium
18 Jan 2021 ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
16 Jan 2021 Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
16 Jan 2021 DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
16 Jan 2021 Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer
16 Jan 2021 Zanidatamab Data Highlight Durable Antitumor Activity in HER2 Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium
16 Jan 2021 ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer
15 Jan 2021 Dompé Announces First Patient Enrolled in Phase 3 trial of Ladarixin, an Oral Investigational CXCR1/2 Inhibitor, in New-Onset Type 1 Diabetes (T1D)
15 Jan 2021 Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis
15 Jan 2021 Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
15 Jan 2021 Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up